SNRNP200: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: SNRNP200

NCBI ID: G23020

SNRNP200

SNRNP200: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

SNRNP200 (HELIC2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. SNRNP200 is a key regulator of gene expression in the brain and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease and Parkinson's disease.

The discovery of SNRNP200 as a potential drug target and biomarker comes from a study by a team of researchers led by Dr. Xinran Li at the University of California, San Diego. The researchers identified SNRNP200 as a key regulator of the expression of the neurotransmitter receptor NG2 in brain cells and found that overexpression of SNRNP200 led to increased NG2 expression and neurotoxicity in brain cells.

The researchers also showed that SNRNP200 was highly expressed in various neurological tissues and was associated with the development of neurodegenerative diseases. They identified SNRNP200 as a potential drug target and biomarker for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target and biomarker, SNRNP200 also has implications for the study of neurodegenerative diseases. The researchers found that SNRNP200 was downregulated in the brains of individuals with Alzheimer's disease and that overexpression of SNRNP200 in brain cells led to increased neurotoxicity and the development of neurodegenerative diseases.

The study of SNRNP200 also has implications for the development of new treatments for neurodegenerative diseases. By identifying SNRNP200 as a potential drug target and biomarker, researchers may be able to develop new treatments that target SNRNP200 and improve the treatment outcomes for neurodegenerative diseases.

In conclusion, SNRNP200 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various neurological disorders, including cancer. The discovery of SNRNP200 comes from a study by a team of researchers led by Dr. Xinran Li at the University of California, San Diego, and has implications for the study of neurodegenerative diseases and the development of new treatments. Further research is needed to fully understand the role of SNRNP200 as a potential drug target and biomarker for neurodegenerative diseases.

Protein Name: Small Nuclear Ribonucleoprotein U5 Subunit 200

Functions: Catalyzes the ATP-dependent unwinding of U4/U6 RNA duplices, an essential step in the assembly of a catalytically active spliceosome (PubMed:35241646). Plays a role in pre-mRNA splicing as a core component of precatalytic, catalytic and postcatalytic spliceosomal complexes (PubMed:28502770, PubMed:28781166, PubMed:29361316, PubMed:30315277, PubMed:29360106, PubMed:29301961, PubMed:30728453, PubMed:30705154). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). Involved in spliceosome assembly, activation and disassembly. Mediates changes in the dynamic network of RNA-RNA interactions in the spliceosome

The "SNRNP200 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRNP200 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets